J&J MedTech Launches Cereglide 42 and 57 Aspiration Catheters for Stroke

February 26, 2026—Johnson & Johnson MedTech announced the United States launch of the Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 delivery aid as part of its aspiration-first stroke portfolio. The company advised that the devices, which complete its Cereglide family, are designed to help physicians reach and remove distal clots in a broad range of ischemic stroke cases.

According to the company, Cereglide 42 and Cereglide 57’s variable-stiffness construction provides flexible distal navigation and supportive proximal control. Both catheters feature hydrophilic coating for reduced friction in tortuous anatomy and a radiopaque tip marker for fluoroscopic visibility. Additionally, they easily track to the M2 with the company’s TruCourse technology.

“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” commented Ameer E. Hassan, DO, in the company’s press release. “In my experience, Cereglide 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes. That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”

Johnson & Johnson MedTech stated that the Innerglide 7 delivery aid is designed to support the advancement of large-bore catheters like Cereglide 71 to distal clot locations. It features a hydrophilic-coated shaft, 1.5-cm soft distal tip, and compatibility with 0.024-inch guidewires.

Dr. Hassan, who is with the Neuroscience Institute at Valley Baptist Medical Center in Harlingen, Texas, stated, “Reaching the M2 segment with large-bore aspiration systems can be technically demanding. Innerglide 7 provides the additional support needed to consistently deliver Cereglide 71 into more distal targets with smoother navigation and less resistance. I am a firm believer in delivery catheter technology like Innerglide.”